Authors
Latest:
Julie Harper, MD: How Our Dermatology Practice is Using TelemedicineA dermatologist and clinical associate professor of dermatology discusses implementing telehealth in dermatology practices.
Latest:
Rivaroxaban: A potential replacement for warfarin?Millions of people in the United States require chronic anticoagulation to prevent thromboembolism secondary to chronic atrial fibrillation (AF), pulmonary hypertension, mechanical valve replacements, and other prothrombotic conditions.
Latest:
Investment Answers from the Gnomes of ZurichA group of investors was recently asked to describe the characteristics of their ideal investments and responded with simple, straightforward answers, including...
Latest:
New Agent Significantly Improves Progression-Free Survival in Patients With Advanced ER+ Breast CancerCombining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.
Latest:
Medication nonadherence and adverse outcomes in CAD patientsNonadherence to beta blockers, statins, or angiotensin-converting enzyme inhibitors is common (21%-29%) among patients with coronary artery disease (CAD). Patients who do not adhere to their medication regimens are at increased risk of mortality, cardiovascular hospitalizations, and revascularization procedures; thus, medication nonadherence should be a target for quality improvement interventions to maximize the outcomes of CAD patients.
Latest:
Epilepsy Market Grows, Widens in 2018A series of newly marketed therapies—from cannabidiol to smartwatches—showed where the future of epilepsy care may grow.
Latest:
Gas pain: A diagnosis in the wavesA 59-year-old Indian man with a medical history significant for orally controlled diabetes presented to the emergency department after experiencing a witnessed seizure.
Latest:
What Comes after a Trillion? Big Numbers and High Anxiety in a Time of Economic UncertaintyWith possible tax increases looming, what can physicians do to safeguard their hard-earned income?
Latest:
Obesity-related hypertensionTo evaluate the interactions between the weight loss drug, sibutramine, and different antihypertensive treatments, we randomly assigned 171 subjects taking 3 antihypertensive treatment regimens to receive sibutramine or placebo. Our study showed for the first time that combination therapy with an angiotensin-converting enzyme inhibitor and a calcium channel blocker is more advantageous than a ß blocker/diuretic-based-regimen with regard to supporting the weight-reducing actions and metabolic changes induced by sibutramine.
Latest:
Prescribing Testosterone Therapy May Increase Risk of Cardiovascular ComplicationsDespite the increasingly widespread use of testosterone therapies, there remains some speculation concerning their long-term effects on overall health.
Latest:
Looking Beyond Seasonal Triggers: Could Eosinophils Be Driving Your Patients' Severe Asthma?Eosinophilic asthma is characterized by elevated levels of eosinophils, which are a direct cause of chronic inflammation in severe asthma.
Latest:
Large-scale clinical epidemiology of stable angina in women and menWe performed a whole-country study using linked health care records in Finland and showed that stable angina as the initial symptomatic manifestation of coronary disease occurs as frequently in women as it does in men. Among easily recognized subgroups, the absolute rates of prognostic outcomes were similarly high in women and men.
Latest:
The Contributors to Suicide, and the Hurdles in Preventing ItOver time, it has become evident that suicide involves a complex mix of genetics, temperament, circumstances, external support, and access to means.
Latest:
Modern Psychiatry and the Folly of Self-DiagnosisThe other day, a patient sent me an e-mail explaining that, after consulting with her spouse and parents, she had changed her mind about taking the medication we discussed during her appointment.
Latest:
Incidence of death and MI associated with stopping clopidogrel after ACSRates of death and myocardial infarction were assessed for a national sample of acute coronary syndrome patients after stopping clopidogrel. In the first 90 days after stopping treatment, patients experienced a nearly twofold increased risk of adverse events compared with subsequent follow-up intervals for patients treated medically without stents and for patients treated with coronary stents. This suggests a possible clopidogrel rebound effect, but additional studies are needed to support this hypothesis and to identify strategies to reduce early events after clopidogrel cessation.
